Recent Advances in the Treatment and Management of Heart Failure: Managed Care Considerations on New and Emerging Therapies

Recent Advances in the Treatment and Management of Heart Failure: Managed Care Considerations on New and Emerging Therapies is organized by National Association of Managed Care Physicians (NAMCP).,This activity is valid from June 1, 2021 to June 1, 2023,Description:,Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. Projections show that by 2030, the prevalence of heart failure will increase 46 percent from recent estimates. HF is the reason for more than 1 million hospitalizations per year and an estimated $31 billion in costs in the U.S. each year. Fortunately for patients with HF, new and emerging therapeutic options have improved both clinical and economic outcomes for these patients and the system.,Upon completion of this activity, participants will be able to:,• Characterize the disease burden of HF in the managed care setting as determined by hospitalizations and other components of morbidity and mortality,• Analyze what managed care and payers need to know about newer therapies in heart failure management,• Examine the latest clinical evidence regarding the safety and efficacy of sGC modulators for treating patients with HF with reduced ejection fraction (HFrEF),• Discuss current economic and logistic barriers to appropriate HF therapy in the managed care setting,• Apply methods to enable optimal cost management of newer heart failure therapy to be realized by multiple heart failure stakeholders including managed care organizations,Additional details will be posted as soon as information is available.